FDA approves Boehringer's once-a-day inhaler drug

(AP)—The Food and Drug Administration has approved a new long-acting inhaler drug from Boehringer Ingelheim to treat people with chronic lung disease.

The agency approved Striverdi Respimat for chronic , which causes bronchitis and emphysema and affects about 24 million people in the U.S. The disease, which is most often caused by smoking, is the third leading cause of death in the U.S., according to the National Institutes of Health.

The FDA approved the drug on Thursday based on a study in 3,104 patients which showed improvements in lung function versus placebo.

The drug will carry a bold warning that it is not approved to treat patients with asthma. Striverdi Respimate is part of a family of medications that have been linked to asthma-related deaths.

5 /5 (1 vote)
add to favorites email to friend print save as pdf

Related Stories

Tudorza pressair approved for COPD

Jul 24, 2012

(HealthDay) -- The Tudorza Pressair (aclidinium bromide) inhaler has been approved by the U.S. Food and Drug Administration to treat narrowing of the lung airways associated with chronic obstructive pulmonary disease (COPD) ...

Anoro ellipta approved for COPD

Dec 18, 2013

(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration.

Adempas approved to treat pulmonary hypertension

Oct 09, 2013

(HealthDay)—Adempas (riociguat) has been approved by the U.S. Food and Drug Administration to treat two types of pulmonary hypertension, characterized by high blood pressure in the arteries of the lungs.

Recommended for you

New system targets germs in donated blood plasma

18 hours ago

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

Judge halts Alzheimer's drug swap until July

Dec 16, 2014

A federal judge has ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer's medication, allegedly in an effort to drive patients to a newer patented drug.

India court blocks Bayer generic drug appeal

Dec 13, 2014

An Indian court has rejected German drug giant Bayer's bid to block a generic version of its blockbuster cancer treatment Nexavar by a local drugmaker, a move hailed by activists on Saturday.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.